# **Bioworld Technology CO., Ltd.**



p-ABL1/2 (Y393/439) Peptide

Cat No.: BS4727P

## Background

The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase.

## **Swiss-Prot**

P00519/P42684

Applications

Blocking

## Specificity

This peptide can be used with studies using BS4727 p-ABL1/2 (Y393/439) pAb.

#### **Purification & Purity**

Synthetic peptide p-ABL1/2 (Y393/439). (Note: the amino acid sequence is proprietary). The purity is > 98%.

### **Product**

1 mg/ml in DI water.

**Storage & Stability** 

Store at  $4 \, \mathbb{C}$  short term. Aliquot and store at  $-20 \, \mathbb{C}$  long term. Avoid freeze-thaw cycles.

### **Research Use**

For research use only, not for use in diagnostic procedure.